Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Yoel Lubell and colleagues consider ethical and economic perspectives on mass drug administration of primaquine to limit transmission of P. falciparum malaria. Please see later in the article for the Editors' Summary.

Original publication

DOI

10.1371/journal.pmed.1001704

Type

Journal article

Journal

PLoS medicine

Publication Date

19/08/2014

Volume

11

Addresses

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, United Kingdom.

Keywords

Humans, Plasmodium falciparum, Malaria, Falciparum, Glucosephosphate Dehydrogenase Deficiency, Primaquine, Antimalarials, Drug Therapy